ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with
histologically or cytologically confirmed advanced solid tumors. This study is designed to
determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of CPI-1205 +
ipilimumab in patients with advanced solid tumors. Patients in Phase 2 will be treated at the
RP2D of CPI-1205 + ipilimumab.
This study was stopped prior to proceeding to Phase 2; no patients were enrolled in Phase 2.